Novel chondroitin sulfate having decreased molecular weight and use thereof

Abstract

An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total. -[4GlcAβ1-3GalNAc(6S)β1]- (wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated)

1 . A chondroitin sulfate having a decreased molecular weight, characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total.
   -[4GlcAβ1-3GalNAc(6S)β1]-   
       (wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated) 
     
     
         2 . A peritoneal dialysis fluid, characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1 . 
     
     
         3 . A compounding agent for a peritoneal dialysis fluid, characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1  as an active ingredient. 
     
     
         4 . An inhibitor of peritoneal disorder caused by a peritoneal dialysis fluid containing glucose and/or a polysaccharide thereof as an osmotic agent, characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1  as an active ingredient. 
     
     
         5 . An inhibitor of production of an advanced glycation end product (AGE), characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1  as an active ingredient. 
     
     
         6 . A reactive oxygen scavenger, characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1  as an active ingredient. 
     
     
         7 . An inhibitor of lipid peroxidation, characterized by containing the chondroitin sulfate having a decreased molecular weight according to  claim 1  as an active ingredient.